Abstract: Liposomal Bupivacaine in Implant-Based Breast Reconstruction: Patient Outcomes and Economics

carcinoma, it is standard perioperative practice for excised tissue obtained from routine reduction mammoplasty procedures to be sent for pathology review. 1 On average, an estimated 0.2–1.1% of all reduction mammoplasty specimens reviewed by pathology is diagnosed with occult malignancy. On occasion, atypical proliferative lesion of variable malignancy potential is also reported, which may become an area of concern given the management of such lesions may be unfamiliar to plastic surgeons. We aimed to provide a review of commonly diagnosed proliferative lesions identified in routine reduction mammoplasty specimens and the best supporting evidence for their subsequent management.